本態性血小板血症（ET）の世界市場レポート 2025年

本態性血小板血症（ET）の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.1％で、11億2,000万米ドルに成長すると予想されます。予測期間中の成長は、本態性血小板血症の認知度の向上と早期診断、血液学的検査の利用可能性の拡大、高齢者人口の増加、ヘルスケア支出の増加、連邦政府の助成金の増加などに起因しています。この期間の主な動向には、技術の進歩、遺伝子プロファイリング、新規標的療法、遠隔医療の進歩、戦略的提携などがあります。

個別化医療の採用拡大が本態性血小板血症（ET）市場の成長を牽引すると予想されます。個別化医療は、個人の遺伝的体質、ライフスタイル、環境要因に基づいて治療や予防戦略を調整するものです。このアプローチは、ゲノム、バイオテクノロジー、データ解析の進歩により、より正確な診断や標的治療を可能にするため、一般的になりつつあります。本態性血小板血症の場合、個別化医療によって遺伝子変異に合わせた治療が可能になり、治療の精度が高まり、患者の転帰が改善します。例えば、2024年2月、個別化医療連合（Personalized Medicine Coalition）は、FDAが希少疾患に対する新しい個別化療法を、2022年にはわずか6件であったのに対し、2023年には16件承認したと報告しました。その結果、個別化医療の採用が増加し、ET市場の成長に寄与しています。

本態性血小板血症市場で事業を展開する企業は、治療効果や患者の転帰を改善し、利用可能な治療法の範囲を拡大するため、bomedemstatの第3相臨床試験を含む新規治療薬の開発にますます注力しています。これらの後期臨床試験では、LSD1阻害剤であるbomedemstatの安全性と有効性が、高度な治療選択肢を必要とする患者を対象に評価されます。例えば、2024年8月にMerck &Co.Inc.は、本態性血小板血症の治療を目的としたbomedemstatの第3相臨床試験であるShorespan-007の開始を発表しました。本試験は、過去に細胞減少療法を受けていない患者を対象としています。本試験の募集は開始され、患者の登録は現在進行中です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の本態性血小板血症（ET）市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の本態性血小板血症（ET）市場：成長率分析
• 世界の本態性血小板血症（ET）市場の実績：規模と成長、2019～2024年
• 世界の本態性血小板血症（ET）市場の予測：規模と成長、2024～2029年、2034年
• 世界の本態性血小板血症（ET）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の本態性血小板血症（ET）市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• インターフェロン
• アナグレリド
• ヒドロキシウレア
• アスピリン
• 世界の本態性血小板血症（ET）市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
• 血液検査
• 骨髄生検
• 遺伝子変異解析
• その他
• 世界の本態性血小板血症（ET）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 研究機関
• 専門クリニック
• 世界の本態性血小板血症（ET）市場：インターフェロンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ペグインターフェロン
• 標準インターフェロン
• 併用療法
• 世界の本態性血小板血症（ET）市場：アナグレリドのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 単剤療法
• アスピリンとの併用
• 用量調整療法
• 世界の本態性血小板血症（ET）市場：ヒドロキシウレアのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 低用量療法
• 高用量療法
• 抗血小板薬との併用
• 世界の本態性血小板血症（ET）市場：アスピリンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 低用量アスピリン
• 高用量アスピリン
• 細胞減量療法との併用

第7章 地域別・国別分析

• 世界の本態性血小板血症（ET）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の本態性血小板血症（ET）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 本態性血小板血症（ET）市場：競合情勢
• 本態性血小板血症（ET）市場：企業プロファイル
  • Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Fresenius Kabi AG
• Incyte Corporation
• Vifor Pharma Management AG
• Bio-Techne Corporation
• Argenx SE
• AOP Orphan Pharmaceuticals AG
• Orchard Therapeutics plc
• Medunik USA.
• Kartos Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 本態性血小板血症（ET）市場2029：新たな機会を提供する国
• 本態性血小板血症（ET）市場2029：新たな機会を提供するセグメント
• 本態性血小板血症（ET）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by the overproduction of platelets in the bone marrow. This condition increases the risk of blood clots, bleeding complications, and potential progression to myelofibrosis or leukemia. Ongoing monitoring and treatment are required to manage symptoms and prevent complications.

The main treatment options for essential thrombocythemia (ET) include interferon, anagrelide, hydroxyurea, and aspirin. Interferon refers to a group of proteins produced by the immune system that help modulate immune responses and inhibit abnormal cell growth. Diagnostic methods for ET include blood tests, bone marrow biopsies, gene mutation analysis, and other procedures. These are used by various end users, including hospitals, research organizations, and specialty clinics.

The essential thrombocythemia (ET) market research report is one of a series of new reports from The Business Research Company that provides essential thrombocythemia (ET) market statistics, including the essential thrombocythemia (ET) industry global market size, regional shares, competitors with the essential thrombocythemia (ET) market share, detailed essential thrombocythemia (ET) market segments, market trends, and opportunities, and any further data you may need to thrive in the essential thrombocythemia (ET) industry. This essential thrombocythemia (ET) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The essential thrombocythemia (ET) market size has grown strongly in recent years. It will grow from $0.83 billion in 2024 to $0.89 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to the rising number of essential thrombocythemia cases, an increase in sickle cell anemia cases, higher investment in research and development, growing awareness among healthcare professionals, and the increasing popularity of related drugs.

The essential thrombocythemia (ET) market size is expected to see strong growth in the next few years. It will grow to $1.12 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to rising awareness and early diagnosis of essential thrombocythemia, greater availability of hematology testing, a growing geriatric population, increased healthcare expenditure, and rising federal funding. Key trends during this period include technological advancements, genetic profiling, novel targeted therapies, advancements in telemedicine, and strategic collaborations.

The increasing adoption of personalized medicine is expected to drive the growth of the essential thrombocythemia (ET) market. Personalized medicine tailors treatment and prevention strategies based on an individual's genetic makeup, lifestyle, and environmental factors. This approach is becoming more popular due to advancements in genomics, biotechnology, and data analytics, which enable more precise diagnostics and targeted therapies. In the case of essential thrombocythemia, personalized medicine allows for therapies tailored to genetic mutations, enhancing treatment accuracy and improving patient outcomes. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, compared to just six in 2022. As a result, the rising adoption of personalized medicine is fueling the growth of the ET market.

Companies operating in the essential thrombocythemia market are increasingly focused on developing novel therapeutics, including Phase 3 clinical trials for bomedemstat, to improve treatment efficacy, patient outcomes, and expand the range of available therapies. These late-stage trials assess the safety and effectiveness of bomedemstat, an LSD1 inhibitor, for patients requiring advanced treatment options. For instance, in August 2024, Merck & Co. Inc., a U.S.-based pharmaceutical company, announced the launch of Shorespan-007, a Phase 3 clinical trial of bomedemstat for treating essential thrombocythemia. The trial targets patients who have not received previous cytoreductive therapy. Recruitment for the trial has begun, and patient enrollment is currently underway.

In January 2023, Merck & Co. Inc. acquired Imago BioSciences Inc. for $1.35 billion to strengthen its hematology portfolio. This acquisition allows Merck to enhance its offerings for essential thrombocythemia and other blood-related disorders by integrating Imago BioSciences' innovative therapies. Imago BioSciences specializes in developing treatments for essential thrombocythemia, bolstering Merck's position in the development of targeted therapies for hematologic diseases.

Major players in the essential thrombocythemia (et) market are Hoffmann-La Roche AG, AbbVie Inc., Johnson & Johnson, Bayer AG, Bristol Myers Squibb Company, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Fresenius Kabi AG, Incyte Corporation, Vifor Pharma Management AG, Bio-Techne Corporation, Argenx SE, AOP Orphan Pharmaceuticals AG, Orchard Therapeutics plc, Medunik USA., and Kartos Therapeutics Inc.

North America was the largest region in the essential thrombocythemia (ET) market in 2024. The regions covered in essential thrombocythemia (ET) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the essential thrombocythemia (ET) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The essential thrombocythemia (ET) market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, monitoring and management services, and patient management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The essential thrombocythemia (ET) market also includes sales of diagnostic products, therapeutic medications, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Essential Thrombocythemia (ET) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on essential thrombocythemia (et) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for essential thrombocythemia (et) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The essential thrombocythemia (et) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Interferon; Anagrelide; Hydroxyurea; Aspirin
• 2) By Diagnosis: Blood Tests; Bone Marrow Biopsy; Gene Mutation Analysis; Other Diagnosis
• 3) By End User: Hospitals; Research Organizations; Specialty Clinics
• Subsegments:
• 1) By Interferon: Pegylated Interferon; Standard Interferon; Combination Therapy
• 2) By Anagrelide: Monotherapy; Combination With Aspirin; Dose-Adjusted Therapy
• 3) By Hydroxyurea: Low-Dose Therapy; High-Dose Therapy; Combination With Antiplatelet Agents
• 4) By Aspirin: Low-Dose Aspirin; High-Dose Aspirin; Combination With Cytoreductive Therapy
• Companies Mentioned: Hoffmann-La Roche AG; AbbVie Inc.; Johnson & Johnson; Bayer AG; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Essential Thrombocythemia (ET) Market Characteristics

3. Essential Thrombocythemia (ET) Market Trends And Strategies

4. Essential Thrombocythemia (ET) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Essential Thrombocythemia (ET) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Essential Thrombocythemia (ET) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Essential Thrombocythemia (ET) Market Growth Rate Analysis
• 5.4. Global Essential Thrombocythemia (ET) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Essential Thrombocythemia (ET) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Essential Thrombocythemia (ET) Total Addressable Market (TAM)

6. Essential Thrombocythemia (ET) Market Segmentation

• 6.1. Global Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferon
• Anagrelide
• Hydroxyurea
• Aspirin
• 6.2. Global Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Bone Marrow Biopsy
• Gene Mutation Analysis
• Other Diagnosis
• 6.3. Global Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Organizations
• Specialty Clinics
• 6.4. Global Essential Thrombocythemia (ET) Market, Sub-Segmentation Of Interferon, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pegylated Interferon
• Standard Interferon
• Combination Therapy
• 6.5. Global Essential Thrombocythemia (ET) Market, Sub-Segmentation Of Anagrelide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination With Aspirin
• Dose-Adjusted Therapy
• 6.6. Global Essential Thrombocythemia (ET) Market, Sub-Segmentation Of Hydroxyurea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Dose Therapy
• High-Dose Therapy
• Combination With Antiplatelet Agents
• 6.7. Global Essential Thrombocythemia (ET) Market, Sub-Segmentation Of Aspirin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Dose Aspirin
• High-Dose Aspirin
• Combination With Cytoreductive Therapy

7. Essential Thrombocythemia (ET) Market Regional And Country Analysis

• 7.1. Global Essential Thrombocythemia (ET) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Essential Thrombocythemia (ET) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Essential Thrombocythemia (ET) Market

• 8.1. Asia-Pacific Essential Thrombocythemia (ET) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Essential Thrombocythemia (ET) Market

• 9.1. China Essential Thrombocythemia (ET) Market Overview
• 9.2. China Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Essential Thrombocythemia (ET) Market

• 10.1. India Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Essential Thrombocythemia (ET) Market

• 11.1. Japan Essential Thrombocythemia (ET) Market Overview
• 11.2. Japan Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Essential Thrombocythemia (ET) Market

• 12.1. Australia Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Essential Thrombocythemia (ET) Market

• 13.1. Indonesia Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Essential Thrombocythemia (ET) Market

• 14.1. South Korea Essential Thrombocythemia (ET) Market Overview
• 14.2. South Korea Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Essential Thrombocythemia (ET) Market

• 15.1. Western Europe Essential Thrombocythemia (ET) Market Overview
• 15.2. Western Europe Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Essential Thrombocythemia (ET) Market

• 16.1. UK Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Essential Thrombocythemia (ET) Market

• 17.1. Germany Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Essential Thrombocythemia (ET) Market

• 18.1. France Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Essential Thrombocythemia (ET) Market

• 19.1. Italy Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Essential Thrombocythemia (ET) Market

• 20.1. Spain Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Essential Thrombocythemia (ET) Market

• 21.1. Eastern Europe Essential Thrombocythemia (ET) Market Overview
• 21.2. Eastern Europe Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Essential Thrombocythemia (ET) Market

• 22.1. Russia Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Essential Thrombocythemia (ET) Market

• 23.1. North America Essential Thrombocythemia (ET) Market Overview
• 23.2. North America Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Essential Thrombocythemia (ET) Market

• 24.1. USA Essential Thrombocythemia (ET) Market Overview
• 24.2. USA Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Essential Thrombocythemia (ET) Market

• 25.1. Canada Essential Thrombocythemia (ET) Market Overview
• 25.2. Canada Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Essential Thrombocythemia (ET) Market

• 26.1. South America Essential Thrombocythemia (ET) Market Overview
• 26.2. South America Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Essential Thrombocythemia (ET) Market

• 27.1. Brazil Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Essential Thrombocythemia (ET) Market

• 28.1. Middle East Essential Thrombocythemia (ET) Market Overview
• 28.2. Middle East Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Essential Thrombocythemia (ET) Market

• 29.1. Africa Essential Thrombocythemia (ET) Market Overview
• 29.2. Africa Essential Thrombocythemia (ET) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Essential Thrombocythemia (ET) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Essential Thrombocythemia (ET) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Essential Thrombocythemia (ET) Market Competitive Landscape And Company Profiles

• 30.1. Essential Thrombocythemia (ET) Market Competitive Landscape
• 30.2. Essential Thrombocythemia (ET) Market Company Profiles
  • 30.2.1. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Essential Thrombocythemia (ET) Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Astellas Pharma Inc.
• 31.7. Fresenius Kabi AG
• 31.8. Incyte Corporation
• 31.9. Vifor Pharma Management AG
• 31.10. Bio-Techne Corporation
• 31.11. Argenx SE
• 31.12. AOP Orphan Pharmaceuticals AG
• 31.13. Orchard Therapeutics plc
• 31.14. Medunik USA.
• 31.15. Kartos Therapeutics Inc.

32. Global Essential Thrombocythemia (ET) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Essential Thrombocythemia (ET) Market

34. Recent Developments In The Essential Thrombocythemia (ET) Market

35. Essential Thrombocythemia (ET) Market High Potential Countries, Segments and Strategies

• 35.1 Essential Thrombocythemia (ET) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Essential Thrombocythemia (ET) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Essential Thrombocythemia (ET) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer